Weekly First-Line Abraxane Yields Benefit

Article

Weekly first-linetherapy with nab-paclitaxel (Abraxane)was well tolerated and showed strongclinical responses in taxane-refractorylocally advanced or metastatic breast cancer,report researchers from the InternationalOncology Network.

DALLAS–Weekly first-linetherapy with nab-paclitaxel (Abraxane)was well tolerated and showed strongclinical responses in taxane-refractorylocally advanced or metastatic breast cancer,report researchers from the InternationalOncology Network (abstract6073). Lead investigator Barry C.Mirtsching, MD, discussed the phase IIopen-label nonrandomized study.

Patients received nab-paclitaxel at 125mg/m2 on days 1, 8, and 15 of a 28-daycycle. HER2-positive patients wereallowed to receive trastuzumab(Herceptin), and underwent cardiacmonitoring at regular intervals. A medianof 4 cycles of chemotherapy (range 1to 15) were administered, and dose wasreduced in about one-fourth of patients,due to toxicity. At analysis, 67 patientshad been treated, and 35 (1 male) wereevaluable for response; 25 were HER2-negative, 9 were HER2-positive, andHER2 status was unavailable for 1 patient.The primary endpoint was ORR.

Good Efficacy, Safety

The CR/PR was 74.3% (26 patients).An additional 8 patients had stable disease.Median time to objective responsewas 3.5 months. Median TTP was 12.6months, and overall survival at 14months (median OS not reached at analysis)was 71.2%.

The CR/PR was 74.3% (26 patients).An additional 8 patients had stable disease.Median time to objective responsewas 3.5 months. Median TTP was 12.6months, and overall survival at 14months (median OS not reached at analysis)was 71.2%.

Dr. Mirtsching and colleagues reportedthat the most common grade 3 toxicitieswere neutropenia (10.4% of patients);neuropathy (6.0%); fatigue(4.5%); and muscle weakness, joint pain,dyspnea, and thrombosis (all at 3%).Grade 4 toxicities were supraventriculartachycardia and vascular disorder, eachoccurring in 1.5% of evaluable patients.

Though the data are preliminary, theinvestigators concluded that they demonstrate"significant efficacy of weeklyAbraxane in the first-line treatment ofmetastatic breast cancer, and a favorablesafety profile."

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content